



DRAFT PROGRAMME

Monday 4th October

| | | | | |
|-----------|---|--|--|---|
| 1300-1330 | Meeting opening: Presidents' address | | | |
| 1330-1430 | <p>Opening Plenary</p> <p>Professor Sir Peter Ratcliffe, Director, Nuffield Department of Medicine at Oxford University and Director of Clinical Research at Francis Crick Institute Nobel Prize Winner 2019</p> <p>Introduced by Chris Winearls</p> | | | |
| 1500-1630 | <p>Session 1 Rapid change, is it better? Quality improvement in the shadow of COVID 19</p> <p>TBC</p> | <p>Session 2 Home dialysis: Improving Access and Outcomes</p> <p>How can we ensure equitable access to home dialysis? - Jenny Shen, Division of Nephrology and Hypertension, David Geffen School of Medicine at UCLA</p> <p>UK CATH results (how to improve PD catheter outcomes) - Martin Wilkie, Sheffield Teaching Hospitals NHS Foundation Trust</p> <p>What has PDOPPS found so far? - Mark Lambie, Keele University</p> <p>Abstract</p> <p>Roundtable discussing improving access to home dialysis, chaired by Simon Davies, Keele University</p> | <p>Session 3 Renal Anaemia: handing over the baton for the next three decades</p> <p>Introduction – Gill Manning & Bintu Bangura</p> <p>The last 3 decades of anaemia treatment - Dr Chris Winearls</p> <p>A NICE story about iron from Wales - Professor Chris Brown</p> <p>The next 30 years of anaemia management - will HiF stabilisers change everything – Matthew Hall, Consultant Nephrologist, Nottingham</p> <p>Panel Question Session</p> <p>Abstract and Q&A</p> | <p>Session 4 The vascular endothelium and the kidney</p> <p>Considering the renal endothelium in perfused kidneys for transplantation - Prof Mike Nicholson:</p> <p>Vascularising kidney organoids - Prof Jamie Davies</p> <p>Why is proteinuria such a powerful risk factor for cardiovascular disease? - Prof Simon Satchell</p> <p>Abstract</p> <p>Q&A and discussion</p> |

1 – subject to change

| | | | | |
|-----------|--|--|--|---|
| 1700-1830 | <p>Session 5 The UK Renal Registry – timely, relevant and linked</p> <p>Welcome and introductions – Dr Graham Lipkin</p> <p>Developments in the big data landscape at the UKRR – Prof Dorothea Nitsch, The Renal Association & LSHTM</p> <p>Timely, relevant and linked: plans for better information – Prof James Medcalf, The Renal Association & University of Leicester, Dr Retha Steenkamp, The Renal Association & Dr Lucy Plumb, The Renal Association & University of Bristol</p> <p>KQuIP: How to achieve change: Supporting kidney quality improvement within emerging regional networks – Rachel Gair, The Renal Association & Catherine Stannard, The Renal Association</p> <p>Abstracts Deriving source populations for adult and paediatric renal centres – Winnie Magadi, The Renal Association</p> <p>Impact of the COVID-19 pandemic on AKI – David Pitcher, The Renal Association</p> <p>Mortality of dialysis patients in the first and second COVID-19 outbreaks – Dr Shalini Santhakumaran, The Renal Association</p> <p>Questions and final comments</p> | <p>Session 6 Understanding adherence and non-adherence in kidney disease including Mallick Lecture</p> <p>Understanding the nature and impact of non-adherence in kidney disease – Angela Taylor - Lead Specialist Renal Counsellor, RSCH</p> <p>Improving Adherence using Eye Movement Desensitisation Reprocessing (EMDR) - Maria Tribe, Renal Psychotherapist & Counsellor, University Hospitals Sussex NHS Foundation Trust</p> <p>Non adherence in Renal Patients – Experience of a Home HD patient – TBC</p> <p>Optimising medicines adherence in transplant patients – TBC</p> <p>Monitoring drug levels and adherence – Experiences in Rheumatology - TBC</p> <p>Mallick Lecture, Gill Manning</p> <p>Panel discussion/Q&A</p> | <p>Session 7 Best clinical abstracts including Raine Award Lecture</p> <p>Raine Award Lecture: Understanding the Cardiovascular Phenotype in advanced chronic kidney disease - Matthew Graham-Brown</p> <p>Abstracts x3</p> <p>Q&A discussion</p> <p>Abstracts x3</p> <p>Q&A discussion</p> | <p>Session 8 Discovering Effective New Targets for Therapy in Kidney Disease</p> <p>Models and big data for target identification and validation in Pharma - Dr Julie Williams, AstraZeneca</p> <p>What makes a good target and how does this translate to clinic? - Dr Shaun Flint, GSK</p> <p>Stem cells as a therapy of the future - TBC</p> <p>Q&A</p> <p>Abstracts x2</p> |
| 1845-1915 | <p>Industry Session 1</p> <p>Astellas</p> | | <p>Industry Session 2</p> <p>Vifor Pharma</p> | |

Tuesday 5th October

| | | | | |
|-----------|---|---|--|--|
| 0900-0930 | Industry Session 3 Becton Dickinson UK | Industry Session 4 Boehringer Ingelheim Ltd | | |
| 0930-1015 | Plenary Session HIV and renal disease Dr Saraladevi Naicker, Professor Emeritus, University of Witwatersrand School of Clinical Medicine | | | |
| 1030-1200 | <p>Session 9 Developing Transplantation for the Future: meeting the need</p> <p>2030 strategy for organ donation and transplantation overview – what’s the vision? – Professor John Forsythe, ODT Medical Director, NHS Blood and Transplant (NHSBT)</p> <p>Landscape of organ donation (to include: legislation/activity/impact of KOS/LD/UKLKSS – Dr Matthew Robb, Principal Statistician, NHSBT)</p> <p>Organ utilisation (including CLU network/new initiatives - Chris Callaghan, Consultant Surgeon, Guy’s & St.Thomas’ NHS Trust/AMD Organ Utilisation, NHSBT)</p> <p>Innovation and technology – Professor Chris Watson, Consultant Surgeon</p> <p>Measuring outcome and experience (including donor-recipient, self-reported outcomes/experience, recipient clinical outcomes) - Dr. Nicholas Torpey, Consultant nephrologist</p> <p>Discussion</p> <p>Abstract x 1</p> | <p>Session 10 Kidney care UK/British Renal Society joint research including Donna Lamping Research Award Lecture</p> <p>BRS Donna Lamping Research Award – Excellent role model, mentor and advocate for using research evidence to change and inform practice - Dr Lina Johansson, NIHR Clinical Lecturer, Imperial College London, and Dietician.</p> <p>Frailty and risk of falling in patients with dialysis dependent chronic kidney disease (CKD) - Pelagia Koufaki, Reader in Clinical Exercise Physiology & Rehabilitation, Centre for Health, Activity and Rehabilitation Research, School of Health Sciences, Queen Margaret University Edinburgh</p> <p>Development and validation of a multi-dimensional self-management scale for use with people with chronic kidney disease on haemodialysis in the UK - Dr Helen Munro Wild, Research Fellow, The University of Hertfordshire</p> <p>Staff assisted Home Haemodialysis (aHHD) as an alternative modality in patients on in-centre Haemodialysis: a feasibility study, TBC</p> <p>The role of illness perceptions in designing psychological interventions for haemodialysis (HD) patients from South Asian backgrounds - Dr Shivani Sharma, Executive Lead: Equality, Diversity and Widening Participation, University of Hertfordshire</p> <p>Questions and answers</p> | <p>Session 11 The renal association international committee- Global responses to COVID19 and impact on renal patients</p> <p>India - Dr Urmila Anandh, Senior Consultant & HOD Nephrology, Yashoda Hospital, India and Prof Arpita Roychowdhury, Institute of Post graduate Medical Education and Research, Kolkata.</p> <p>Israel - Dr Ayelet Grupper , Nephrology and kidney transplantation, Tel Aviv Medical Center, Israel.</p> <p>Managing COVID positive renal patients around the world – lessons from cases - Prof Neil Turner, Edinburgh University.</p> <p>Establishing CAPD services in Nigeria - Dr David Lewis, Salford.</p> <p>Q&A</p> | <p>Session 12 Novel cellular models of the kidney for basic research and drug discovery</p> <p>Creating human functional renal tracts in the laboratory - Professor Adrian Woolf, University of Manchester.</p> <p>GlomSpheres: A scalable, flexible, 3D model of the kidney glomerulus, demonstrating suitability for rapid drug-screening in diverse disease models - Dr Jack Tuffin, University of Bristol.</p> <p>Towards quantitative whole-kidney 3D imaging in preclinical drug development - Dr Mette Viberg</p> <p>Abstracts x2</p> <p>Q&A</p> |
| 1200-1300 | Lunch | | | |
| 1300-1330 | Industry Session 5 AstraZeneca | Industry Session 6 Astellas | | |

3 – subject to change

| | | | | |
|-----------|--|--|--|---|
| 1330-1500 | <p>Session 13 Should we screen and treat asymptomatic kidney transplant candidates for coronary artery disease to join the waiting list? Perspectives from different stakeholders</p> <p>Introduction – Dr Adnan Sharif and Dr Ailish Nimmo</p> <p>Different perspectives</p> <ul style="list-style-type: none"> • The Nephrologist: Matt Graham Brown, University of Leicester • The Renal Transplant Surgeon: Karen Stevenson, Queen Elizabeth University Hospital, Glasgow • The Cardiologist: Christopher Baker, Imperial College Healthcare, London • The Anaesthetist: Nicoletta Fossati, St. George’s Hospital, London. • The Patient: Kidney Care UK representative <p>Q&A panel discussion</p> <p>Closing remarks – Dr Adnan Sharif and Dr Ailish Nimmo</p> | <p>Session 14 Kidney Health Inequalities in the UK – reflecting and learning from the pandemic, reducing in the future</p> <p>Welcome and introduction</p> <p>What we know about health inequalities in kidney care: Amjid Ali</p> <p>Round table discussion Young people: Holly Loughton Ethnicity: TBC Ethnicity: TBC Mental health: Simon Arday, Specialist Renal Mental Health, Kings</p> <p>Q&A</p> <p>Interactive session with audience voting</p> <p>Breakout rooms to discuss possible ways in which renal teams could identify and reduce health inequalities through practice, education or quality improvement/research Facilitators: Fiona Loud and Nicola Thomas</p> <p>Return to main session for conclusions and close</p> | <p>Session 15 GIRFT and the RSTP: shaping the future of renal services</p> <p>Introduction – Chairs</p> <p>GIRFT: Key findings – Graham Lipkin and Will McKane</p> <p>GIRFT: Recommendations - Graham Lipkin and Will McKane</p> <p>RSTP Overview - Neil Ashman</p> <p>RSTP: CKD – Smeeta Sinha</p> <p>RSTP: Transplantation – Nick Torpey</p> <p>RTSP: Dialysis services – Albert Power</p> <p>RSTP: Acute Kidney Injury - TBC</p> <p>Q&A panel discussion</p> | <p>Session 16 Basement membrane disorders in the kidney – diagnosis and therapeutic updates , including De Wardner lecture</p> <p>National screening programme for Alport syndrome - Elizabeth Watson or Maggie Williams, Principal Clinical Scientist, Bristol Genetics Laboratory</p> <p>Clinical trials in Alport Syndrome - Oliver Gross, Professor of Nephrology, University Medicine Goettingen</p> <p>RA De Wardener Lecture – Prof Rachel Lennon</p> <p>Abstracts x3</p> |
| 1530-1700 | Moderated poster session 1 | | | |

| | | | | | |
|------------------|--|--|---|---|---|
| <p>0900-1030</p> | <p>Session 17 How can big data drive clinical practice</p> <p>How data informs need to perform randomised controlled trials of common sense interventions - Perry Wilson, Yale University School of Medicine</p> <p>What can large data tell us about cardiorenal effects of stopping RAS inhibition? - Juan Jesus Carrero, Professor of Epidemiology, Karolinska Institute</p> <p>COVID19 and kidney disease- insights from OpenSAFELY - Laurie Tomlinson, London School of Hygiene and Tropical Medicine</p> | <p>Session 18 The KDIGO BP target for CKD <120 mmHg systolic is appropriate: a debate</p> <p>The KDIGO systolic BP target <120 mm Hg for CKD is inappropriate in the UK: Con - Indranil Dasgupta, Consultant Nephrologist, University Hospitals Birmingham NHS FT.</p> <p>The KDIGO systolic BP target <120 mm Hg for CKD is inappropriate in the UK: Pro - Charles Tomson, retired nephrologist in Newcastle, member of KDIGO BP in CKD guidelines development group</p> <p>Rebuttal and moderated discussion.</p> | <p>Session 19 Recent advances in glomerulonephritis including the Chandos Lecture Award</p> <p>Chandos Lecture; Update in membranous glomerulonephritis - Dr Megan Griffiths</p> <p>Best glomerulonephritis abstracts: x4</p> | <p>Session 20 Metabolomics and kidney disease</p> <p>Metabolic reprogramming in disease: Can we use genetic epidemiology to guide laboratory studies? – Dr Emma Vincent. University of Bristol.</p> <p>Metabolic profiling the human immune system - Dr Nick Jones, University of Swansea.</p> <p>TBC</p> <p>Abstracts x2</p> | <p>Session 21 Patient Involvement and Current Clinical Trials in Haemodialysis</p> <p>Participating in a haemodialysis trial: perspectives from two patients (names TBC) - Facilitated by Dr Katherine Hull, Clinical Research Fellow and Renal SpR, Leicester Hospitals.</p> <p>How to deliver successful patient and public involvement in a trial - Dr Amanda Stranks, Communications and Strategy Lead, NIHR Cambridge BRC</p> <p>Prepare for Kidney Care: optimising recruitment to challenging trials with the QuinteT Recruitment Intervention Dr Leila Roosenhas, Senior Lecturer in Qualitative Health Science, Bristol Population Health Science Institute.</p> <p>NightLife: A study of in-centre nocturnal haemodialysis. A partnership approach to participation - Professor James Burton, Honorary Consultant Nephrologist and Chief Investigator, the NightLife Trial</p> <p>H4RT: lessons from delivering an RCT in haemodialysis before and during the COVID-19 pandemic - Dr Fergus Caskey, Consultant Senior Lecturer, University of Bristol and Chief Investigator, Prepare for Kidney Care Trial.</p> <p>PHOSPHATE: A new trial for an old problem. The importance of evidence to inform practice - Dr Rona Smith, Senior Research Fellow and Honorary Consultant in Nephrology, University of Cambridge.</p> <p>Panel Q&A</p> <p>Oral abstract presentation</p> |
| <p>1045-1200</p> | <p>Session 22 Honouring Donal O’Donoghue’s Legacy in the Kidney Community</p> <p>Chairs Introduction</p> | | | | |

| | |
|-----------|--|
| | <p>Networks, Pathways and Maps</p> <p>Reflections on Donal’s vision for the Greater Manchester kidney care transformational journey - Jenny Scott, Joint lead for Greater Manchester Renal Project, including Salford Royal NHS FT Trust/Manchester Royal Infirmary/West Pennine Health Authority/NW Kidney Patient Association</p> <p>Developing the medical workforce - Dr Matthew Graham-Brown, NIHR Academic Clinical Lecturer in Renal Medicine, University of Leicester and Honorary Consultant Nephrologist, John Walls Renal Unit, UHL</p> <p>Contribution to national policy: ‘You know what you have to do, now go out there and do it’ - Dr P E Stevens, Consultant Nephrologist & Medical Examiner, Chair, South East Clinical Senate, East Kent Hospitals University NHS Foundation Trust</p> <p>Sustainable healthcare - Dr. Frances Mortimer, Medical Director, Centre for sustainable healthcare</p> <p>Honouring the International contributions of Donal O’Donoghue: People, Policies and Personality - Adeera Levin, Professor of Medicine, University of British Columbia, Head Division of Nephrology, Executive Director BC Renal , Consulting Nephrologist St Paul’s Hospital</p> |
| 1200-1300 | Lunch |
| 1300-1530 | TBC |

DRAFT

Thursday 7th October

| | | | | |
|-----------|--|--|--|--|
| 0900-0930 | Industry Session 7 Alexion | Industry Session 8 Fresenius | | |
| 0930-1100 | Moderated poster session 2 | | | |
| 1100-1115 | Break | | | |
| 1115-1230 | <p>Session 23 Rare kidney diseases – increasing awareness and defining new therapies</p> <p>RaDaR Natural History: Big Data to study Rare Renal Disease - Daniel Gale</p> <p>Primary hyperoxaluria – a new era of treatment - Sally Hulton</p> <p>dRTA - disease mechanisms and treatments - Ben Walsh</p> <p>Selected relevant abstracts</p> | <p>Session 24 Frailty in CKD: a multidisciplinary approach.</p> <p>Chairs introductions</p> <p>Introduction to CGA and evidence re: outcomes/importance experience - Simon Conroy Geriatrician/Honorary Professor of Geriatric Medicine, UCL</p> <p>Rapid fire input from MDT in relation to CGA for renal: Cathy Pogson, Renal Pharmacist, Portsmouth Hospitals University NHS Trust Saba Boyer-Masfari, Renal Dietitian, Guy's and St Thomas' NHS Foundation Trust Dr Hannah Young, Dept of Research and Innovation, University Hospitals of Leicester NHS Trust. Dept of Respiratory Sciences, University of Leicester Lisa Ancliffe, Senior Specialist Occupational Therapist, Guy's and St Thomas' NHS Foundation Trust</p> <p>CGA for renal - current state of the evidence and future directions for research and care - Dr Andrew Christopher Nixon, Department of Renal Medicine, Lancashire Teaching Hospitals NHS Foundation Trust</p> <p>Panel discussion and Q&A</p> | <p>Session 25 UK Renal Trials Network update</p> <p>Introduction - William G. Herrington</p> <p>Ongoing UK renal trials - Patrick Mark, Institute of Cardiovascular & Medical Sciences, University of Glasgow</p> <p>Refining outcomes for kidney disease progression: use of eGFR slopes & handling acute effects on eGFR - Lesley Inker, Tufts University School of Medicine, Boston</p> <p>Mineralocorticoid receptor antagonism in CKD & dialysis: proven benefits & ongoing trial questions - Peter Rossing, Steno Diabetes Centre, Copenhagen</p> <p>RECOVERY trial: even more data on preventing Covid-19 related acute kidney injury from a platform trial - Richard Haynes, Nuffield Department of Population Health, University of Oxford</p> <p>Questions and discussion for last 2 talks - Rona Smith</p> | <p>Session 26 Self-Care and Point-of-Care – Innovative strategies to support our new virtual world</p> <p>Background to Self-Care - Austen El-Osta</p> <p>Patient perspective - Expert Patient</p> <p>Novel Strategies Smart-Phone albuminuria testing - Roseline Agiekum</p> <p>Home finger-prick blood tests - Dimitrios Moutzouris</p> <p>Point-of-care blood tests - Sunil Bhandari</p> <p>Home blood pressure monitoring with digital support - Georgie Thomas</p> <p>Personal health records and digital engagement - Henry Totts</p> <p>Peer Educator/Health Advocate - Denis Onyango</p> <p>Abstract</p> <p>Breakout Groups – Disease area integration Early CKD Advanced CKD Transplant</p> <p>Feedback / Panel Discussion</p> |
| 1230-1300 | Lunch | | | |
| 1300-1330 | Industry Session 9 AstraZeneca | Industry Session 10 Travere Therapeutics | | |

7 – subject to change

| | | | | |
|-----------|---|---|---|--|
| 1330-1430 | <p>Session 27 Supporting young adults to live well with kidney disease</p> <p>How to provide psychosocial support: lessons from the Patient Empowerment, self Esteem, Employability and Resilience (PEEER) project - Dr Arvind Nagra, Southampton Children's Hospital</p> <p>Let's talk about Sex, baby - Brett Dowds, Kidney Wales/Young Adult Kidney Group and Dr Kate Wiles, Department of Women's Health and Renal Medicine, Barts Health NHS Trust</p> <p>Peer support: lessons from the Young Adult Kidney group - Holly Loughton, Young Adult Kidney Group</p> <p>Oral abstracts x3</p> | <p>Session 28 Patient and AHPs experience of weight management in people living with kidney disease</p> <p>TBC</p> | <p>Session 29 Clinical-Pathological Correlation</p> <p>Introduction - Chairs</p> <p>A new approach to de novo minimal change disease in pregnancy - Dr. Sarah Gleeson, Imperial Renal and Transplant Centre, Imperial College Healthcare NHS Trust; Department of Immunology and Inflammation, Imperial College, London</p> <p>Radiation nephropathy is associated with a glomerular thrombotic microangiopathy and progression to end stage kidney disease - Dr. Isabela Bertoni, Oxford Kidney Unit, Oxford University Hospitals NHS Foundation Trust</p> <p>Evidence for IgG4 and ANCA disease association. A case study of MPO positive vasculitis with IgG4 positive plasma cells on renal biopsy in a patient with a background of pancreatic IgG4 disease - Dr. Jennifer Whitehead, Department of Nephrology, South Tees Trust.</p> <p>Closing remarks - Chairs</p> | <p>Session 30 Best Science abstracts</p> <p>6x oral abstract presentations + discussion</p> |
| 1430-1500 | Break | | | |
| 1500-1630 | <p>Session 31 Interventional Nephrology (IN)</p> <p>Why do you need IN? - Tushar Vachharajani, Clinical Professor of Medicine, Cleveland Clinic Lerner College of Medicine of CWRU, Director of Global Nephrology, Glickman Urological & Kidney Institute</p> <p>Setting up an IN service in the UK - Rauri Clarkn South Tyneside Sunderland Foundation NHS Trust</p> | <p>Session 32 Shared Decision Making – still room for improvement, but how? Including Claire Main, Leadership award</p> <p>Jane Macdonald Leadership Award – Claire Main</p> <p>SDM background and intro, including using tech to gauge opinion and ideas in the room – Eleri Wood, Nurse Consultant, KCH</p> <p>Learning from patients: two patients giving their reflections of the impacts of SDM done well and</p> | <p>Session 33 It's Friday, it's 5:30 and the phone is ringing...</p> <p>Poisonings – when and who to dialyse? - Dr Emma Montgomery, Consultant Nephrologist, Freeman Hospital Newcastle</p> <p>Dialysis refusal – hot and cold decision making - Dr Stephen Potts, Consultant in Transplant Psychiatry, Royal Infirmary of Edinburgh</p> | <p>Session 34 What's new in Acute Kidney Injury?</p> <p>Introduction to session Dr Noble and Professor Selby</p> <p>Preventing medication-induced AKI: the NINJA quality improvement programme - Professor Stuart Goldstein, Professor of Paediatrics and Director of the Center for Acute Care Nephrology Cincinnati Childrens Hospital, USA</p> <p>A matter of definition –the harmonised KDIGO</p> |

| | | | | |
|-----------|--|---|--|--|
| | <p>and Bhriugu Sood, Epsom and St.Helier University Hospitals NHS Trust</p> <p>UK IN training past, present and future - Shalabh Srivastava, South Tyneside Sunderland Foundation NHS Trust</p> <p>Breakout sessions</p> <p>1. Staff Nurse accreditation and Intervention program - Debra Sweeney and Carol Allan , South Tyneside Sunderland Foundation NHS Trust</p> <p>2. How many ways can you insert a medical PD catheter - Bhriugu Sood, Epsom and St.Helier University Hospitals NHS Trust and Haroon Ayub, South Tyneside Sunderland Foundation NHS Trust</p> <p>3. PoCUS - James Andrews South Tyneside Sunderland Foundation NHS Trust</p> <p>MDT Interactive cases</p> <p>Case 1 "PD case" Bhriugu Sood, Pritpal Verdie and Subash Somalanka, Epsom and St.Helier University Hospitals NHS Trust</p> <p>Case 2 "Fibrin Sheath" Saeed Ahmed and Rauri Clark, South Tyneside Sunderland Foundation NHS Trust</p> <p>Are we ready for UKDIN?" "Close & contacts" IN interest group in UKRA - Saeed Ahmed South Tyneside Sunderland Foundation NHS Trust and Rebecca Suckling,</p> | <p>the small changes professionals can make to their communication and approach to do it better - Maz Ali, patient and peer educator, Birmingham and another TBC</p> <p>Learning from good examples: two professionals giving their reflections on implementing small projects which increase the sharing of decisions a) using patient view in consultations and b) coaching - TBC</p> <p>Live round table discussion and questions from the floor</p> | <p>Complex hyponatraemia – how to manage? – Dr Conall O’Seaghdha, Consultant Nephrologist, Beaumont Hospital, Dublin</p> | <p>classification of AKI and AKD versus their application using ‘real-world’ data - Dr Samira Bell, Senior Lecturer and Honorary Consultant Nephrologist, University of Dundee</p> <p>Can SGLT2-inhibitors protect against AKI? Professor Volker Vallon, Professor of Medicine University of California, San Diego (UCSD), USA</p> <p>The evidence that sodium bicarbonate improves outcomes in AKI patients with acidosis - Professor Lui Forni, Professor of Critical Care Medicine, University of Surrey</p> <p>Live Q&A discussion</p> |
| 1630-1700 | Meeting close | | | |